{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:50:52Z","timestamp":1782885052756,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Infectious Diseases Research Institute, Seattle, WA","award":["AI064745"],"award-info":[{"award-number":["AI064745"]}]},{"name":"Infectious Diseases Research Institute, Seattle, WA","award":["AL007"],"award-info":[{"award-number":["AL007"]}]},{"name":"Infectious Diseases Research Institute, Seattle, WA","award":["AL019"],"award-info":[{"award-number":["AL019"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.vaccine.2013.10.083","type":"journal-article","created":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T08:45:20Z","timestamp":1383727520000},"page":"19-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evaluating the efficacy of rBmHAT\u03b1c as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation"],"prefix":"10.1016","volume":"32","author":[{"given":"Gajalakshmi","family":"Dakshinamoorthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramaswamy","family":"Kalyanasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.10.083_bib0005","series-title":"Bridging the gap. Report of the Director General","author":"World Health Report","year":"1995"},{"issue":"3","key":"10.1016\/j.vaccine.2013.10.083_bib0010","doi-asserted-by":"crossref","first-page":"e34077","DOI":"10.1371\/journal.pone.0034077","article-title":"Biochemical characterization and evaluation of a Brugia malayi small heat shock protein as a vaccine against lymphatic filariasis","volume":"7","author":"Dakshinamoorthy","year":"2012","journal-title":"PLoS One"},{"issue":"31","key":"10.1016\/j.vaccine.2013.10.083_bib0015","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1016\/j.vaccine.2010.05.012","article-title":"Identification and characterization of nematode specific protective epitopes of Brugia malayi TRX towards development of synthetic vaccine construct for lymphatic filariasis","volume":"28","author":"Madhumathi","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2013.10.083_bib0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/RRTM.S13679","article-title":"Multivalent vaccine formulation with BmVAL-1 and BmALT-2 confer significant protection against challenge infections with Brugia malayi in mice and jirds","volume":"2011","author":"Kalyanasundaram","year":"2011","journal-title":"Res Rep Trop Med"},{"issue":"4","key":"10.1016\/j.vaccine.2013.10.083_bib0025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.exppara.2007.02.017","article-title":"Brugia malayi: comparison of protective immune responses induced by Bm-alt-2 DNA, recombinant Bm-ALT-2 protein and prime-boost vaccine regimens in a jird model","volume":"116","author":"Thirugnanam","year":"2007","journal-title":"Exp Parasitol"},{"issue":"8","key":"10.1016\/j.vaccine.2013.10.083_bib0030","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1128\/IAI.72.8.4707-4715.2004","article-title":"Novel phage display-based subtractive screening to identify vaccine candidates of Brugia malayi","volume":"72","author":"Gnanasekar","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.10.083_bib0035","article-title":"Large extracellular loop of tetraspanin as a potential vaccine candidate for filariasis","volume":"October","author":"Dakshinamoorthy","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2013.10.083_bib0040","article-title":"Multivalent fusion protein vaccine for lymphatic filariasis","author":"Dakshinamoorthy","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2013.10.083_bib0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1529-8019.2009.01222.x","article-title":"Safety and efficacy of vaccines","volume":"22","author":"Bartlett","year":"2009","journal-title":"Dermatol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2013.10.083_bib0050","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1542\/peds.2010-1722C","article-title":"Integrating safety and efficacy evaluation throughout vaccine research and development","volume":"127","author":"Curlin","year":"2011","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vaccine.2013.10.083_bib0055","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.coi.2005.05.005","article-title":"Vaccinology at the beginning of the 21st century","volume":"17","author":"Wack","year":"2005","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2013.10.083_bib0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0169-409X(98)00008-8","article-title":"Aluminum compounds as vaccine adjuvants","volume":"32","author":"Gupta","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2013.10.083_bib0065","first-page":"831486","article-title":"Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development","author":"Sayers","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"4","key":"10.1016\/j.vaccine.2013.10.083_bib0070","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","article-title":"Towards an understanding of the adjuvant action of aluminium","volume":"9","author":"Marrack","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2013.10.083_bib0075","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/ni712","article-title":"Toll-like receptors control activation of adaptive immune responses","volume":"2","author":"Schnare","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2013.10.083_bib0080","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev.immunol.21.120601.141040","article-title":"Tolerogenic dendritic cells","volume":"21","author":"Steinman","year":"2003","journal-title":"Annu Rev Immunol"},{"issue":"43","key":"10.1016\/j.vaccine.2013.10.083_bib0085","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1016\/j.vaccine.2009.07.081","article-title":"Enhanced humoral and type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion","volume":"27","author":"Baldwin","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.083_bib0090","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/978-90-481-9078-2_14","article-title":"Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants","volume":"53","author":"Fox","year":"2010","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.vaccine.2013.10.083_bib0095","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4269\/ajtmh.1989.40.598","article-title":"Immunity to larval Brugia malayi in BALB\/c mice: protective immunity and inhibition of larval development","volume":"40","author":"Abraham","year":"1989","journal-title":"Am J Trop Med Hyg"},{"issue":"27","key":"10.1016\/j.vaccine.2013.10.083_bib0100","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1016\/j.vaccine.2007.04.078","article-title":"Imject\u00ae Alum is not aluminum hydroxide adjuvant or aluminum phosphate adjuvant","volume":"25","author":"Hem","year":"2007","journal-title":"Vaccine"},{"issue":"2-3","key":"10.1016\/j.vaccine.2013.10.083_bib0105","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.micron.2011.07.012","article-title":"Alhydrogel(R) adjuvant, ultrasonic dispersion and protein binding: a TEM and analytical study","volume":"43","author":"Harris","year":"2012","journal-title":"Micron"},{"issue":"4","key":"10.1016\/j.vaccine.2013.10.083_bib0110","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.vaccine.2012.11.044","article-title":"Disparate adjuvant properties among three formulations of alum","volume":"31","author":"Cain","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2013.10.083_bib0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4110\/in.2013.13.1.10","article-title":"Directly modulates Murine B lymphocytes to produce IgG1 isotype","volume":"13","author":"Jin","year":"2013","journal-title":"Immune Network"},{"issue":"7","key":"10.1016\/j.vaccine.2013.10.083_bib0120","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1586\/14760584.2013.811201","article-title":"Vaccine adjuvants","volume":"12","author":"Reed","year":"2013","journal-title":"Expert Rev Vac"},{"issue":"12","key":"10.1016\/j.vaccine.2013.10.083_bib0125","doi-asserted-by":"crossref","first-page":"E1122","DOI":"10.1073\/pnas.1300392110","article-title":"Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells","volume":"110","author":"McKee","year":"2013","journal-title":"Proc Nat Acad Sci USA"},{"issue":"3","key":"10.1016\/j.vaccine.2013.10.083_bib0130","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1096\/fj.11-184556","article-title":"Antigen depot is not required for alum adjuvanticity","volume":"26","author":"Hutchison","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.vaccine.2013.10.083_bib0135","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2013.10.083_bib0140","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1128\/IAI.66.6.2859-2865.1998","article-title":"Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen","volume":"66","author":"Richards","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.10.083_bib0145","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1128\/IAI.68.5.3034-3035.2000","article-title":"Role of gamma Interferon and Interleukin-4 in host defense against the human filarial parasite Brugia malayi","volume":"68","author":"Babu","year":"2000","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2013.10.083_bib0150","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.exppara.2011.08.005","article-title":"The adjuvant-free immunoprotection of recombinant filarial protein Abundant Larval Transcript- 2 (ALT-2) in Mastomys coucha and the immunoprophylactic importance of its putative signal sequence","volume":"129","author":"Sharmila","year":"2011","journal-title":"Exp Parasitol"},{"issue":"2","key":"10.1016\/j.vaccine.2013.10.083_bib0155","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1128\/IAI.00128-10","article-title":"Granuloma formation around filarial larvae triggered by host responses to an excretory\/secretory antigen","volume":"79","author":"Dash","year":"2011","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2013.10.083_bib0160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4049\/jimmunol.0802047","article-title":"IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host","volume":"183","author":"Liu","year":"2009","journal-title":"J Immunol"},{"issue":"36","key":"10.1016\/j.vaccine.2013.10.083_bib0165","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1016\/j.vaccine.2007.06.049","article-title":"Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response","volume":"25","author":"Hansen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.083_bib0170","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1749-6632.1993.tb44015.x","article-title":"Novel adjuvant strategies for experimental malaria and AIDS vaccines","volume":"690","author":"Alving","year":"1993","journal-title":"Ann NY Acad Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2013.10.083_bib0175","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/clinids\/2.3.370","article-title":"Vaccine adjuvants","volume":"2","author":"Edelman","year":"1980","journal-title":"Rev Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13014904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13014904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T11:38:53Z","timestamp":1596800333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13014904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0264410X13014904"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.083","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the efficacy of rBmHAT\u03b1c as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}